Skip to main content
SpringerLink
Log in
Book cover

Inflammatory Bowel Disease: From Bench to Bedside pp 409–429Cite as

New diagnostic approaches in inflammatory bowel disease

  • Chapter

  • 1276 Accesses

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   119.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   159.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol 1989; 24(Suppl.): 2–6.

    Google Scholar 

  2. Allchin WH. Ulcerative colitis. Proc Roy Soc Med 1909; 2: 59–75.

    PubMed  CAS  Google Scholar 

  3. Dalziel Tk. Chronic interstitial enteritis. Br Med J 1913; 2: 1068–70.

    Google Scholar 

  4. Crohn BB, Ginzburg L, Oppenheimer GD. Regional ileitis. J Am Med Assoc 1932; 99: 1323–9.

    Google Scholar 

  5. Sachar DB, Andrews HA, Farmer RG et al. Proposed classification of patients subgroups in Crohn’s disease. Gastroenterol Int 1992; 5: 141–54.

    Google Scholar 

  6. Targan S, Murphy LK. Serologic and mucosal markers of ulcerative colitis and Crohn’s disease: implications of pathophysiology for diagnosis. In: Scholmerich J, Kruis W, Goebell H et al, eds. Inflammatory Bowel Diseases — Pathophysiology as a Basis of Treatment. Dordrecht: Kluwer Academic Publishers, 1993: 283–6.

    Google Scholar 

  7. Rotter JI, Yang H. Delineating the major aetiological risk factors for IBD: the genetic susceptibilities. In: Scholmerich J, Kruis W, Goebell H et al, eds. Inflammatory Bowel Diseases — Pathophysiology as a Basis of Treatment. Dordrecht: Kluwer Academic Publishers, 1993: 9–18.

    Google Scholar 

  8. Yang H, Rotter JI. The genetics of inflammatory bowel disease: genetic predispositions, disease markers, and genetic heterogeneity. In: Targan SR, Shanahan F, eds. Inflammatory Bowel Disease: From Bench to Bedside. Baltimore: Williams & Wilkins, 1994: 32–64.

    Google Scholar 

  9. Satsangi J, Jewell DP, Rosenberg WMC, Bell JI. Genetics of inflammatory bowel disease. Gut 1994; 35: 696–700.

    PubMed  CAS  Google Scholar 

  10. Vasiliauskas EA, Kam LY, Karp LC, Gaiennie J, Yang HY, Targan SR. Marker antibody expression stratifies Crohn’s disease into immunologically homogeneous subgroups with distinct clinical characteristics. Gut 2000; 47: 487–96.

    PubMed  CAS  Google Scholar 

  11. Duerr RH, Targan SR, Landers CJ, Sutherland LR, Shanahan F. Anti-neutrophil cytoplasmic antibodies in ulcerative colitis: comparison with other colitides/diarrheal illnesses. Gastroenterology 1991; 100: 1590–6.

    PubMed  CAS  Google Scholar 

  12. Shanahan F, Duerr RH, Rotter JI et al. Neutrophil auto-antibodies in ulcerative colitis: familial aggregation and genetic heterogeneity. Gastroenterology 1992; 103: 456–61.

    PubMed  CAS  Google Scholar 

  13. Yang HY, Rotter JI, Toyoda H et al. Ulcerative colitis: a genetically heterogeneous disorder defined by genetic (HLA class II) and subclinical (antineutrophil cytoplasmic antibodies) markers. J Clin Invest 1993; 92: 1080–4.

    PubMed  CAS  Google Scholar 

  14. Satsangi J, Landers CJ, Welsh KI, Koss K, Targan S, Jewell DP. The presence of anti-neutrophil antibodies reflects clinical and genetic heterogeneity within inflammatory bowel disease. Inflam Bowel Dis 1998; 4: 18–26.

    Article  CAS  Google Scholar 

  15. Sendid B, Quinton JF, Charrier G, Goulet O, Cortot A, Grandbastien B, Poulain D, Colombel JF. Anti-Saccharomyces cerevisiae mannan antibodies in familial Crohn’s disease. Am J Gastroenterol 1998; 93: 1306–10.

    PubMed  CAS  Google Scholar 

  16. Sutton CL, Yang H, Li Z, Rotter JI, Targan SR, Braun J. Familial expression of anti-Saccharomyces cerevisiae mannan antibodies in affected and unaffected relatives of patients with Crohn’s disease. Gut 2000; 46: 58–63.

    PubMed  CAS  Google Scholar 

  17. Jennette JC, Hogan S, Wilkman AS, Tuttle R, Jones D, Falk RJ. Anti-neutrophil cytoplasmic autoantibody (ANCA) disease associations. Scand J Gastroenterol 1989; 24(Suppl. 158): 206–7 (A39).

    Google Scholar 

  18. Saxon A, Shanahan F, Landers C, Ganz T, Targan S. A distinct subset of antineutrophil cytoplasmic antibodies is associated with inflammatory bowel disease. J Allergy Clin Immunol 1990; 86: 202–10.

    PubMed  CAS  Google Scholar 

  19. Duerr RH, Targan SR, Landers CJ et al. Neutrophil cytoplasmic antibodies: a link between primary sclerosing cholangitis and ulcerative colitis. Gastroenterology 1991; 100: 1385–91.

    PubMed  CAS  Google Scholar 

  20. Seibold F, Weber P, Klein R, Berg PA, Wiedmann KH. Clinical significance of antibodies against neutrophils in patients with inflammatory bowel disease and primary sclerosing cholangitis. Gut 1992; 33: 657–62.

    PubMed  CAS  Google Scholar 

  21. Colombel JF, Reumaux D, Duthilleul P et al. Antineutrophil cytoplasmic autoantibodies in inflammatory bowel diseases. Gastroenterol Clin Biol 1992; 16: 656–60.

    PubMed  CAS  Google Scholar 

  22. Cambridge G, Rampton DS, Stevens TRJ, McCarthy DA, Kamm M, Leaker B. Anti-neutrophil antibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut 1992; 33: 668–74.

    PubMed  CAS  Google Scholar 

  23. Lo SK, Fleming KA, Chapman RW. Prevalence of anti-neutrophil antibody in primary sclerosing cholangitis and ulcerative colitis using an alkaline phosphatase technique. Gut 1992; 33: 1370–3.

    PubMed  CAS  Google Scholar 

  24. Oudkerk Pool M, Ellerbroek PM, Ridwan BU et al. Serum antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease are mainly associated with ulcerative colitis. A correlation study between perinuclear antineutrophil cytoplasmic autoantibodies and clinical parameters, medical, and surgical treatment. Gut 1993; 34: 46–50.

    PubMed  CAS  Google Scholar 

  25. Hardarson S, Labrecque DR, Mitros FA, Neil GA, Goeken JA. Antineutrophil cytoplasmic antibody in inflammatory bowel and hepatobiliary diseases. Am J Clin Pathol 1993; 99: 277–81.

    PubMed  CAS  Google Scholar 

  26. Proujansky R, Fawcett PT, Gibney KM, Trcem WR, Hyams JS. Examination of anti-neutrophil cytoplasmic antibodies in childhood inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1993; 17: 193–7.

    Article  PubMed  CAS  Google Scholar 

  27. Reumaux D, Colombel JF, Delecourt L, Noel LH, Cortot A, Duthilleul P. Anti-neutrophil cytoplasmic auto-antibodies (ANCA) in patients with ulcerative colitis (UC): influence of disease activity and familial study. Adv Exp Med Biol 1993; 336: 515–18.

    PubMed  CAS  Google Scholar 

  28. Broekroelofs J, Mulder AH, Nelis GF, Esterveld BD, Ervaert JWC, Allenberg CGM. Anti-neutrophil cytoplasmic antibodies (ANCA) in sera from patients with inflammatory bowel disease (IBD): relation to disease pattern and disease activity. Dig Dis Sci 1994; 39: 545–9.

    PubMed  CAS  Google Scholar 

  29. Mulder AHL, Broekroelofs J, Horst G, Limburg PC, Nelis GF, Kallenberg CGM. Anti-neutrophil cytoplasmic antibodies (ANCA) in inflammatory bowel disease: characterization and clinical correlates. Clin Exp Immunol 1994; 95: 490–7.

    Article  PubMed  CAS  Google Scholar 

  30. Sung JY, Chan FKL, Lawton J et al. Anti-neutrophil cytoplasmic antibodies (ANCA) and inflammatory bowel diseases in Chinese. Dig Dis Sci 1994; 39: 886–92.

    PubMed  CAS  Google Scholar 

  31. Vecchi M, Bianchi MB, Sinico RA et al. Antibodies to neutrophil cytoplasm in Italian patients with ulcerative colitis: sensitivity, specificity and recognition of putative antigens. Digestion 1994; 55: 34–9.

    PubMed  CAS  Google Scholar 

  32. Winter HS, Landers CJ, Winkelstein A, Vidrich A, Targan SR. Anti-neutrophil cytoplasmic antibodies in children with ulcerative colitis. J Pediatr 1994; 125: 707–11.

    PubMed  CAS  Google Scholar 

  33. Patel RT, Stokes R, Birch D, Ibbotson J, Keighley MRB. Influence of total colectomy on serum antineutrophil cytoplasmic antibodies in inflammatory bowel disease. Br J Surg 1994; 81: 724–6.

    PubMed  CAS  Google Scholar 

  34. Seibold F, Slametschka D, Gregor M, Weber P. Neutrophil autoantibodies: a genetic marker in primary sclerosing cholangitis and ulcerative colitis. Gastroenterology 1994; 107: 532–6.

    PubMed  CAS  Google Scholar 

  35. Boerr LA, Sambuelli AM, Katz S et al. Clinical heterogeneity of ulcerative colitis in relation to frequency of pANCA reactivity. Gastroenterology 1995; 108: A785.

    Google Scholar 

  36. Lee JCW, Lennard-Jones JE, Cambridge G. Antineutrophil antibodies in familial inflammatory bowel disease. Gastroenterology 1995; 108: 428–33.

    PubMed  CAS  Google Scholar 

  37. Vasiliauskas EA, Plevy SE, Landers CJ et al. Perinuclear antineutrophil cytoplasmic antibodies in patients with Crohn’s disease define a clinical subgroup. Gastroenterology 1996; 110: 1810–19.

    PubMed  CAS  Google Scholar 

  38. Quinton J-F, Sendid B, Reumaux D et al. Anti-Saccharomyces cerevisiae mannan antibodies combined with anti-neutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut 1998; 42: 788–91.

    Article  PubMed  CAS  Google Scholar 

  39. Ruemmele FM, Targan SR, Levy G, Dubinsky M, Braun J, Seidman EG. Diagnostic accuracy of serological assays in pediatric inflammatory bowel disease. Gastroenterology 1998; 115: 822–9.

    PubMed  CAS  Google Scholar 

  40. Hoffenberg EJ, Fidanza S, Sauaia A. Serologic testing for inflammatory bowel disease. J Pediatr 1999; 134: 447 52.

    PubMed  Google Scholar 

  41. Fleshner PR, Vasiliauskas EA, Kam LY et al. High level perinuclear antineutrophil cytoplasmic antibody (pANCA) in ulcerative colitis patients before colectomy predicts the development of chronic pouchitis after ileal pouch anal anastomosis. Gut 2001 49: 671–7.

    PubMed  CAS  Google Scholar 

  42. Sandborn WJ, Loftus EV, Colombel JF et al. Utility of perinuclear anti-neutrophil cytoplasmic antibodies (pANCA), anti-Saccharomyces cerevisiae (ASCA), and anti-pancreatic antibody (APA) as serologic markers in a population based cohort of patients with Crohn’s disease (CD) and ulcerative colitis (UC). Gastroenterology 2000; 118:A106 (no. 696).

    Google Scholar 

  43. Deusch K, Oberstadt K, Schaedel W, Weber M, Classen M. p-ANCA as a diagnostic marker in ulcerative colitis. Adv Exp Med Biol 1993; 336: 527 31.

    PubMed  Google Scholar 

  44. Taylor K, Plevy SE, Yang H et al. ANCA pattern and LTA haplotype relationship to clinical responses to anti-TNF antibody treatment in Crohn’s disease. Gastroenterology 2001; 120: 1347–55.

    PubMed  CAS  Google Scholar 

  45. Vasiliauskas E, Targan SR. Do pANCA define a clinical subgroup in patients with Crohn’s disease? Gastroenterology 1997; 112: 316–17.

    Google Scholar 

  46. Vidrich A, Lee J, James E, Cobb L, Targan S. Segregation of pANCA antigenic recognition by DNase treatment of neutrophils: ulcerative colitis, type 1 autoimmune hepatitis, and primary sclerosing cholangitis. J Clin Immunol 1995; 15: 293–9.

    PubMed  CAS  Google Scholar 

  47. Vasiliauskas EA, Kam LY, Abreu-Martin MT et al. An open-label pilot study of low-dose thalidomide in chronically-active, steroid-dependent Crohn’s disease. Gastroenterology 1999; 117: 1278–87.

    PubMed  CAS  Google Scholar 

  48. Ellerbroek PM, Oudkerk Pool M, Ridwan BU et al. Neutrophil cytoplasmic antibodies (p-ANCA) in ulcerative colitis. J Clin Pathol 1994; 47: 257–62.

    PubMed  CAS  Google Scholar 

  49. Billing P, Tahir S, Calfin B et al. Nuclear localization of the antigen detected by ulcerative colitis-associated perinuclear antineutrophil cytoplasmic antibodies. Am J Pathol 1995; 147: 979–87.

    PubMed  CAS  Google Scholar 

  50. Eggena M, Cohavy O, Parseghian MH, et al. Identification of histone H1 as a cognate antigen of the ulcerative colitis-associated marker antibody pANCA. J Autoimmun 2000; 14: 83–97.

    PubMed  CAS  Google Scholar 

  51. Gordon LK, Eggena M, Targan SR, Braun J. Mast cell and neuroendocrine cytoplasmic autoantigen(s) detected by monoclonal pANCA antibodies. Clin Immunol 2000; 94: 42–50.

    PubMed  CAS  Google Scholar 

  52. Cohavy O, Bruckner D, Gordon LK et al. Colonic bacteria express an ulcerative colitis pANCA-related protein epitope. Infect Immun 2000; 68: 1542–8.

    PubMed  CAS  Google Scholar 

  53. Targan SR, Landers CJ, Cobb L, MacDermott RP, Vidrich A. Perinuclear anti-neutrophil cytoplasmic antibodies are spontaneously produced by mucosal B cells of ulcerative colitis patients. J Immunol 1995; 155: 3262–7.

    PubMed  CAS  Google Scholar 

  54. Plevy SE, Landers CJ, Vasiliauskas EA, Targan SR, Vidrich A. Alterations in serum immunoglobulin (Ig) G subclasses provide evidence for distinct immune responses in pANCA positive Crohn’s disease patients. Gastroenterology 1996; 110: A993.

    Google Scholar 

  55. Kam LY, Vasiliauskas EA, Landers CJ, Targan SR. Magnitude of response to Remicade™ correlates with marker antibody expression. Gastroenterology 1999; 116: A744 (G3232).

    Google Scholar 

  56. Vasiliauskas EA, Plevy SE, Targan SR. Stratification of Crohn’s disease by antineutrophil cytoplasmic antibodies (ANCA) & anti-Saccharomyces cerevisiae antibody (ASCA) distinguishes phenotypic subgroups. Gastroenterology 1997; 112: A1112.

    Google Scholar 

  57. McKenzie H, Main J, Pennington CR, Parratt D. Antibody to selected strains of Saccharomyces cerevisiae (baker’s and brewer’s yeast) and Candida albicans in Crohn’s disease. Gut 1990; 31: 536–8.

    PubMed  CAS  Google Scholar 

  58. Barclay GR, McKenzie H, Pennington J, Parratt D, Pennington CR. The effect of dietary yeast on the activity of stable chronic Crohn’s disease. Scand J Gastroenterol 1992; 27(Suppl.): 196–200.

    PubMed  CAS  Google Scholar 

  59. Sendid B, Colombel JF, Jacquinot PM et al. Specific antibody response to oligomannosidic epitopes in Crohn’s disease. Clin Diagn Lab Immunol 1996; 3: 219–26.

    PubMed  CAS  Google Scholar 

  60. Dubinsky MC, Ofman JJ, Urman M, Targan SR, Seidman EG. Clinical utility of serodiagnostic testing in suspected pediatric inflammatory bowel disease. Am J Gastroenterol 2001; 96: 758–65.

    PubMed  CAS  Google Scholar 

  61. Lindberg E, Magnusson KE, Tysk C, Järnerot G. Antibody (IgG, IgA, and IgM) to baker’s yeast (Saccharomyces cerevisiae), yeast mannan, gliadin, ovalbumin and betalactoglobulin in monozygotic twins with inflammatory bowel disease. Gut 1992; 33: 909–13.

    PubMed  CAS  Google Scholar 

  62. Darroch CJ, Christmas SE, Barnes RMR. In vitro human lymphocyte proliferative responses to a glycoprotein of the yeast Saccharomyces cerevisiae. Immunology 1994; 81: 247–52.

    PubMed  CAS  Google Scholar 

  63. Young CA, Sonnenberg A, Burns EA. Lymphocyte proliferation response to baker’s yeast in Crohn’s disease. Digestion 19 1994; 55: 40–3.

    CAS  Google Scholar 

  64. Taylor KD, Li Z, Barry M et al. Tumor necrosis factor microsatellite haplotype a11b4c1d3e3 is associated with anti-Saccharomyces cerevisiae antibody (ASCA) across clinical forms of inflammatory bowel disease. Gastroenterology 1998; 114: A1098 (G4492).

    Google Scholar 

  65. Lubinski SM, LaBuda MC, Cho JH, Hanauer SB, Bayless TM, Brant SR. Anti-Saccharomyces Antibodies (ASCA) are highly positive in familial Crohn’s disease (CD). Gastroenterology 1999; 116: A766 (G3323).

    Google Scholar 

  66. Yang H, Taylor K, Lin YC, Targan SR, Rotter JI. Magnitude of anti-Saccharomyces cerevisiae antibody (ASCA) expression is linked, in Crohn’s disease, families to the major histocompatibility complex (MHC) region. Gastroenterology 2000; 118: A339 (no. 1833).

    Google Scholar 

  67. Plevy SE, Vasiliauskas EA, Taylor K et al. The Crohn’s disease associated tumor necrosis factor (TNF) microsatellite a2blc2d4el haplotype and anti-Saccharomyces cerevisiae antibody (ASCA)define medically resistant forms of ulcerative colitis. Gastroenterology 1997; 112: A1062.

    Google Scholar 

  68. Duchmann R, Kaiser I, Hermann E et al. Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD). Clin Exp Immunol 1995; 102: 448–55.

    Article  PubMed  CAS  Google Scholar 

  69. Cohavy O, Harth G, Horwitz M et al. Identification of a novel mycobacterial histone H1 homologue (HupB) as an antigenic target of pANCA monoclonal antibody and serum immunoglobulin A from patients with Crohn’s disease. Infect Immun 1999; 67: 6510–17.

    PubMed  CAS  Google Scholar 

  70. Murry PR, Rosenthal KS, Kobayashi GS, Pfaller MA. Medical Microbiology, 4th edn. St Louis, Missouri: Mosby-Yearbook Inc, 2002: 11–24.

    Google Scholar 

  71. Singh SP, Upshaw Y, Abdullah T, Singh SR, Klebba PE. Structural relatedness of enteric bacterial porins assessed with monoclonal antibodies to Salmonella typhimurium OmpD and OmpC. J Bacteriol 1992; 174: 1965–73.

    PubMed  CAS  Google Scholar 

  72. Painbeni E, Caroff M, Rouviere-Yaniv J. Alternations of the outer membrane composition in Escherichia lacking the histone-like protein HU. Proc Natl Acad Sci 1997; 94: 6712–17.

    PubMed  CAS  Google Scholar 

  73. Sutton CL, Kim J, Yamane A et al. Identification of a novel bacterial sequence associated with Crohn’s disease. Gastroenterology 2000; 119: 23–31.

    PubMed  CAS  Google Scholar 

  74. Landers CJ, Braun J, Targan SR. I2, a mucosal Crohn’s disease (CD) associated bacterial antigen, induces both humoral and T-cell responses in CD patients: I2 induced interferon-Γ (INF-Γ) production is associated with higher levels of serum IgA reactivity. Gastroenterology 2000; 118: A347. (no. 1870).

    Google Scholar 

  75. Stevens TR, Winrow VR, Blake DR, Rampton DS. Circulating antibodies to heat-shock protein 60 in Crohn’s disease and ulcerative colitis. Clin Exp Immunol 1992; 90: 271–4.

    Article  PubMed  CAS  Google Scholar 

  76. Halbwachs-Mecarelli L, Nusbaum P, Noël LH et al. Anti-neutrophil cytoplasmic antibodies (ANCA) directed against cathepsin G in ulcerative colitis, Crohn’s disease and primary sclerosing cholangitis. Clin Exp Immunol 1992; 90: 79–84.

    Article  PubMed  CAS  Google Scholar 

  77. Mayet WJ, Hermann E, Finsterwalder J et al. Antibodies to cathepsin G in Crohn’s disease. Eur J Clin Invest 1992; 22: 427–33.

    Article  PubMed  CAS  Google Scholar 

  78. Fricke H, Birkhofer A, Folwaczny C, Meister W, Scriba PC. Characterization of antigens from the human exocrine pancreatic tissue (Pag) relevant as target antigens for auto-antibodies in Crohn’s disease [See comments]. Eur J Clin Invest 1999; 29: 41–5.

    PubMed  CAS  Google Scholar 

  79. Seibold F, Weber P, Jenss H, Wiedmann KH. Antibodies to a trypsin sensitive pancreatic antigen in chronic inflammatory bowel disease: specific markers for a subgroup of patients with Crohn’s disease. Gut 1991; 32: 1192–7.

    PubMed  CAS  Google Scholar 

  80. Seibold F, Scheurlen M, Muller A, Jenss H, Weber P. Impaired pancreatic function in patients with Crohn’s disease with and without pancreatic autoantibodies. J Clin Gastroenterol 1996; 22: 202–6.

    PubMed  CAS  Google Scholar 

  81. Seibold F, Mork H, Tanza S et al. Pancreatic autoantibodies in Crohn’s disease: a family study. Gut 1997; 40: 481–4.

    PubMed  CAS  Google Scholar 

  82. Folwaczny C, Noehl N, Endres SP, Loeschke K, Fricke H. Antineutrophil and pancreatic autoantibodies in first-degree relatives of patients with inflammatory bowel disease. Scand J Gastroenterol 1998; 33: 523–8.

    PubMed  CAS  Google Scholar 

  83. Propst A, Propst T, Herold M, Vogel W, Judmaier G. Interleukin-1 receptor antagonist in differential diagnosis of inflammatory bowel diseases. Eur J Gastroenterol Hepatol 1995; 7: 1031–6.

    PubMed  CAS  Google Scholar 

  84. Cassini-Raggi V, Kam L, Chong YT, Fiocchi C, Pizarro TT, Cominelli F. Mucosal imbalance of IL-1 and IL-1 receptor antagonist in inflammatory bowel disease. J Immunol 1995; 154: 2434–40.

    Google Scholar 

  85. Mansfield JC, Holden H, Tarlow JK et al. Novel genetic association between ulcerative colitis and the anti-inflammatory cytokine interleukin-1 receptor antagonist. Gastro-enterology 1994; 106: 637–42.

    CAS  Google Scholar 

  86. Tountas NA, Casini-Raggi V, Yang H et al. Functional and ethnic association of allele 2 of the interleukin-1 receptor antagonist gene in ulcerative colitis. Gastroenterology 1999; 117: 806–13.

    PubMed  CAS  Google Scholar 

  87. Roussomoustakaki M, Satsangi J, Welsh K et al. Genetic markers may predict disease behavior in patients with ulcerative colitis. Gastroenterology 1997; 112: 1845–53.

    PubMed  CAS  Google Scholar 

  88. Papo M, Quer JC, Gutierrez C et al. Genetic heterogeneity within ulcerative colitis determined by an interleukin-1 receptor antagonist gene polymorphism and antineutrophil cytoplasmic antibodies. Eur J Gastroenterol Hepatol 1999; 11: 413–20.

    PubMed  CAS  Google Scholar 

  89. Hacker UT, Gomolka M, Keller E et al. Lack of association between an interleukin-1 receptor antagonist gene polymorphism and ulcerative colitis. Gut 1997; 40: 623–7.

    PubMed  CAS  Google Scholar 

  90. Heresbach D, Alizadeh M, Dabadie A et al. Significance of interleukin-1 beta and interleukin-1 receptor antagonist genetic polymorphism in inflammatory bowel diseases. Am J Gastroenterol 1997; 92: 1164–9.

    PubMed  CAS  Google Scholar 

  91. Bioque G, Crusius JB, Koutroubakis I et al. Allelic polymorphism in IL-1 beta and IL-1 receptor antagonist (IL-lRa) genes in inflammatory bowel disease. Clin Exp Immunol 1995; 102: 379–83.

    Article  PubMed  CAS  Google Scholar 

  92. Stokkers PC, van Aken BE, Basoski N, Reitsma PH, Tytgat GN, Van Deventer SJ. Five genetic markers in the inter-leukin 1 family in relation to inflammatory bowel disease. Gut 1998; 43: 33–9.

    Article  PubMed  CAS  Google Scholar 

  93. Hirv K, Seyfarth M, Uibo R et al. Polymorphisms in tumour necrosis factor and adhesion molecule genes in patients with inflammatory bowel disease: associations with HLA-DR and-DQ alleles and subclinical markers. Scand J Gastroenterol 1999; 34: 1025–32.

    PubMed  CAS  Google Scholar 

  94. Heresbach D, Alizadeh M, Reumaux D et al. Are HLA-DR or TAP genes genetic markers of severity in ulcerative colitis? J Autoimmun 1996; 9: 777–84.

    PubMed  CAS  Google Scholar 

  95. Bouma G, Crusius JB, Garcia-Gonzalez MA et al. Genetic markers in clinically well defined patients with ulcerative colitis (UC). Clin Exp Immunol 1999; 115: 294–300.

    PubMed  CAS  Google Scholar 

  96. Bouma G, Poen AC, Garcia-Gonzalez MA et al. HLA-DRB1*03, but not the TNFA-308 promoter gene polymorphism, confers protection against fistulising Crohn’s disease. Immunogenctics 1998; 47: 451–5.

    CAS  Google Scholar 

  97. Vasiliauskas EA. Pcdiatric inflammatory bowel disease. Curr Treat Options Gastroenterol 2000; 3: 403–25.

    PubMed  Google Scholar 

  98. Pimentel M, Chang M, Chow EJ et al. Identification of a prodromal period in Crohn’s disease but not ulcerative colitis. Am J Gastroenterol 2000; 95: 3458–62.

    PubMed  CAS  Google Scholar 

  99. Burbige EJ, Huang SH, Bayless TM. Clinical manifestations of Crohn’s disease in children and adolescents. Pediatrics 1975; 55: 866–71.

    PubMed  CAS  Google Scholar 

  100. Gryboski J, Hillemeier C. Inflammatory bowel disease in children. Med Clin N Am 1980; 64: 1185–202.

    PubMed  CAS  Google Scholar 

  101. Whittington PF, Barnes HV, Bayless TM. Medical management of Crohn’s disease in adolescence. Gastroenterology 1977; 72: 1338–44.

    PubMed  CAS  Google Scholar 

  102. Kanof ME, Lake AM, Bayless TM. Decreased height velocity in children and adolescents before the diagnosis of Crohn’s disease. Gastroenterology 1988; 95: 1523–7.

    PubMed  CAS  Google Scholar 

  103. Motil KJ, Grand RJ, Davis-Kraft L, Ferlic LL, Smith EO. Growth failure in children with inflammatory bowel disease: a prospective study. Gastroenterology 1993; 105: 681–91.

    PubMed  CAS  Google Scholar 

  104. Markowitz J, Grancher K, Rosa J, Aiges H, Daum F. Growth failure in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1993; 16: 373–80.

    Article  PubMed  CAS  Google Scholar 

  105. Griffiths AM, Nguyen P, Smith C, MacMillan JH, Sherman PM. Growth and clinical course of children with Crohn’s disease. Gut 1993; 34: 939–43.

    PubMed  CAS  Google Scholar 

  106. Ward MM, Polisson RP. A meta-analysis of the clinical manifestations of older-onset sytemic lupus erythematosus. Arthritis Rheum 1989; 32: 1226–32.

    PubMed  CAS  Google Scholar 

  107. Vasiliauskas E. Serum immune markers in inflammatory bowel disease. Gastroenterol Endosc News 1997; Oct: 35–7.

    Google Scholar 

  108. Lockhart-Mummery HE, Morson BC. Crohn’s disease (regional enteritis) of the large intestine and its distinction from ulcerative colitis. Gut 1960; 1: 87–105.

    PubMed  CAS  Google Scholar 

  109. Lewin K, Swales JD. Granulomatous colitis and atypical ulcerative colitis: histological features, behavior, and prognosis. Gastroenterology 1966; 50: 211–23.

    Google Scholar 

  110. Price AB. Overlap in the spectrum of non-specific inflammatory bowel disease —’ colitis indeterminate‘. J Clin Pathol 1978; 31: 567–77.

    PubMed  CAS  Google Scholar 

  111. Tanaka M, Riddell RH. The pathological diagnosis and differential diagnosis of Crohn’s disease. Hepatogastroenterology 1990; 37: 18–31.

    PubMed  CAS  Google Scholar 

  112. Shivananda S, Hordijk ML, Ten Kate FJW, Probert CSJ, Mayberry JF. Differential diagnosis of inflammatory bowel disease. Scand J Gastroenterol 1991; 26: 167–73.

    PubMed  CAS  Google Scholar 

  113. Yang H, McElree C, Roth M-P, Shanahan F, Targan SR, Rotter JI. Familial empirical risks for inflammatory bowel disease: differences between Jews and non-Jews. Gut 1993; 34: 517–24.

    PubMed  CAS  Google Scholar 

  114. Atkinson KG, Owen DA, Wankling G. Restorative proctocolecotmy and indeterminate colitis. Am J Surg 1994; 167: 516–18.

    PubMed  CAS  Google Scholar 

  115. Yang H, Vora DK, Targan SR, Toyoda H, Beaudet AL, Rotter JI. Intercellular adhesion molecule 1 gene associations with immunologic subsets of inflammatory bowel disease. Gastroenterology 1995; 109: 440–8.

    PubMed  CAS  Google Scholar 

  116. Boon N, Hanaucr SB, Kisiel J. The clinical significance of pANCA and ASCA in indeterminate colitis. Gastroenterology 1999; 116: A671 (G2925).

    Google Scholar 

  117. Landers CJ, Yang H, Lin YC, Vasiliauskas EA, Braun J, Targan SR. IgA serum antibody reactivity with 12, a novel Crohn’s disease marker: anti-12 level is independent from ASCA and ANCA levels even though IgA ASCA positivity is correlated with anti-I2 positivity. Gastroenterology 2000; 118: A348 (no. 1871).

    Google Scholar 

  118. Sandborn WJ, Landers CJ, Tremaine WJ, Targan SR. Antineutrophil cytoplasmic antibody correlates with chronic pouchitis after ileal pouch anal anastomosis. Am J Gastroenterol 1995; 90: 740–7.

    PubMed  CAS  Google Scholar 

  119. Sandborn WJ, Landers CJ, Tremaine WJ, Targan SR. Association of antineutrophil cytoplasmic antibodies with resistance to treatment of left-sided ulcerative colitis: results of a pilot study. Mayo Clin Proc 1996; 71: 431–6.

    PubMed  CAS  Google Scholar 

  120. Vecchi M, Bianchi MB, Calabresi C, Meucci G, Tatarella M, De Franchis R. Long-term observation of the peri-nuclear anti-neutrophil cytoplasmic antibody status in ulcerative colitis patients. Scand J Gastroenterol 1998; 33: 170–3.

    PubMed  CAS  Google Scholar 

  121. Vecchi M, Gionchetti P, Bianchi MB et al. p-ANCA and development of pouchitis in ulcerative colitis patients after proctocolectomy and ileoanal pouch anastomosis. Lancet 1994; 344: 886–7.

    PubMed  CAS  Google Scholar 

  122. Reumaux D, Colombel JF, Heresbach D et al. Antineutrophil cytoplasmic auto-antibodies in sera from patients after proctocolectomy for ulcerative colitis. Gastroenterology 1993; 104: A769.

    Google Scholar 

  123. Rump JA, Wörner I, Roth M, Schölmerich J, Hänsch M, Peter HH. p-ANCA of undefined specificity in ulcerative colitis: correlation to disease activity and therapy. Adv Exp Med Biol 1993; 336: 507–13.

    PubMed  CAS  Google Scholar 

  124. Aitola P, Miettinen A, Mattila A, Matikainen M, Soppi E. The effect of proctocolectomy on serum antineutrophil cytoplasmic antibodies in patients with ulcerative colitis. Gastroenterology 1995; 108: A768.

    Google Scholar 

  125. Yang H, Plevy SE, Landers CJ et al. The R241 allele of ICAM-1 is associated with a distinct clinical subgroup of Crohn’s disease (CD) characterized by perinuclear ANCA (pANCA) production. Gastroenterology 1996; 110: A1049.

    Google Scholar 

  126. Toyoda H, Wang SJ, Yang HY et al. Distinct associations of HLA class II genes with inflammatory bowel disease. Gastroenterology 1993; 104: 741–8.

    PubMed  CAS  Google Scholar 

  127. Facklis K, Plevy SE, Vasiliauskas EA et al. A Crohn’s disease associated genetic marker is seen in medically unresponsive ulcerative colitis and may be associated with pouch-specific complications. Dis Colon Rectum 1999; 42: 601–6.

    PubMed  CAS  Google Scholar 

  128. Fleshner PR, Taylor KD, Yang H et al. Chronic pouchitis after ileal pouch-anal anastomosis for ulcerative colitis (UC) is associated with the interferon-γ receptor-α (IFNγRα) gene independent of perinuclear antineutrophil cytoplasmic antibody (pANCA) level. Gastroenterology 2000; 118: A338. (no. 1827).

    Google Scholar 

  129. Giaffer MH, Clark A, Holdsworth CD. Antibodies to Saccharomyces cerevisiae in patients with Crohn’s disease and their possible pathogenic importance. Gut 1992; 33: 1071–5.

    PubMed  CAS  Google Scholar 

  130. Freeman HJ. Atypical perinuclear antineutrophil cytoplasmic antibodies (p-ANCA) in patients with Crohn’s disease. Gastroenterology 1998; 114: A979.

    Google Scholar 

  131. Norlén BJ, Krause U, Bergman L. An epidemiological study of Crohn’s disease. Scand J Gastroenterol 1970; 5(Suppl): 385–90.

    PubMed  Google Scholar 

  132. Lee FI, Costello FT. The changing incidence of Crohn’s disease in Blackpool 1969–1983. Front Gastrointest Res 1986; 11: 102–13.

    CAS  Google Scholar 

  133. Halme L, von Smitten K, Husa A. The incidence of Crohn’s disease in the Helsinki metropolitan area during 1975–1985. Ann Chir Gynaecol 1989; 78: 115–19.

    PubMed  CAS  Google Scholar 

  134. Fleischer DE, Grimm IS, Friedman LS. Inflammatory bowel disease in older patients. Med Clin N Am 1994; 78: 1303–19.

    PubMed  CAS  Google Scholar 

  135. Devlin HB, Datta D, Dellipiani AW. The incidence and prevalence of inflammatory bowel disease in North Tees Health District. World J Surg 1980; 4: 183–93.

    PubMed  CAS  Google Scholar 

  136. Polito JM, Childs B, Mellits ED, Tokayer AZ, Harris ML, Bayless TM. Crohn’s disease: influence of age at diagnosis on site and clinical type of disease. Gastroenterology 1996; 111: 580–6.

    PubMed  Google Scholar 

  137. Puntis J, McNeish AS, Allan RN. Long term prognosis of Crohn’s disease with onset in childhood and adolescence. Gut 1984; 25: 329–36.

    PubMed  CAS  Google Scholar 

  138. Cooke WT. Long term prognosis of Crohn’s disease with onset in childhood and adolescence. Gut 1984; 25: 1303–5.

    PubMed  CAS  Google Scholar 

  139. Gupta S, Saverymuttu SH, Keshavarzian A, Hodgson HJ. Is the pattern of inflammatory bowel disease different in the elderly? Age Ageing 1985; 14: 366–70.

    PubMed  CAS  Google Scholar 

  140. O’Keefe EA, Wright JP, Froggatt J, Zabow D. Medium-term follow-up of ulcerative colitis in Cape Town. S Afr Med J 1989; 76: 139–41.

    PubMed  CAS  Google Scholar 

  141. Mashako MN, Cezard JP, Navarro J et al. Crohn’s disease lesions in the upper gastrointestinal tract: correlation between clinical, radiological, endoscopic, and histological features in adolescents and children. J Pediatr Gastroenterol Nutr 1989; 8: 442–6.

    Article  PubMed  CAS  Google Scholar 

  142. Lenaerts C, Roy CC, Vaillancourt M, Weber AM, Morin CL, Seidman E. High incidence of upper gastrointestinal tract involvement in children with Crohn disease. Pediatrics 1989;83: 777–81.

    PubMed  CAS  Google Scholar 

  143. Vasiliauskas EA, Kam L, Gaiennie J, Targan SR. Early onset Crohn’s Disease (CD) differs from late adult onset CD — immunologic evidence. J Pediatr Gastroenterol Nutr 1998; 27: 471 (A33).

    Google Scholar 

  144. Monsen U, Bernell O, Johansson C, Hellers G. Prevalence of inflammatory bowel disease among relatives of patients with Crohn’s disease. Scand J Gastroenterol 1991; 26(Suppl.): 302–6.

    PubMed  CAS  Google Scholar 

  145. Bayless TM, Tokayer AZ, Polito JM, Quaskey SA, Mellits ED, Harris ML. Crohn’s disease: concordance for site and clinical type in affected family members-potential hereditary influences. Gastroenterology 1996; 111: 573–9.

    PubMed  CAS  Google Scholar 

  146. Polito JM, Rees RC, Childs B, Mendeloff AI, Harris ML, Bayless TM. Preliminary evidence for genetic anticipation in Crohn’s disease. Lancet 1996; 347: 798–800.

    PubMed  Google Scholar 

  147. Satsangi J, Grootscholten C, Holt H, Jewell DP. Clinical patterns of familial inflammatory bowel disease. Gut 1996; 38: 738–41.

    PubMed  CAS  Google Scholar 

  148. Peeters M, Nevens H, Baert F et al. Familial aggregation in Crohn’s disease: increased age-adjusted risk and concordance in clinical characteristics. Gastroenterology 1996; 111: 597–603.

    PubMed  CAS  Google Scholar 

  149. Yanase Y, Tango T, Okumura K, Tada T, Kawasaki T. Lymphocyte subsets identified by monoclonal antibodies in healthy children. Pediatr Res 1986; 20: 1147–51.

    PubMed  CAS  Google Scholar 

  150. Ettenger RB, Blifeld C, Prince H et al. The pediatric nephrologist’s dilemma: growth after renal transplantation and its interaction with age as a possible immunologic variable. J Pediatr 1987; 111: 1022–5.

    PubMed  CAS  Google Scholar 

  151. Ettenger RB. Children are different: the challenges of pediatric renal transplantation. Am J Kidney Dis 1992; 20: 668–72.

    PubMed  CAS  Google Scholar 

  152. Cole GF, Stuart CA. A long perspective on childhood multiple sclerosis. Dev Med Child Neurol 1995; 37: 661–6.

    Article  PubMed  CAS  Google Scholar 

  153. Tucker LB, Menon S, Schaller JG, Isenberg DA. Adult-and childhood-onset systemic lupus erythematosus: a comparison of onset, clinical features, serology, and outcome. Br J Rheumatol 1995; 34: 866–72.

    PubMed  CAS  Google Scholar 

  154. Janwityanujit S, Totemchokchyakarn K, Verasertniyom O, Vanichapuntu M, Vatanasuk M. Age-related differences on clinical and immunological manifestations of SLE. Asian Pacific J Allergy Immunol 1995; 13: 145–9.

    CAS  Google Scholar 

  155. Host A, Jacobsen HP, Halken S, Holmenlund D. The natural history of cow’s milk protein allergy/intolerance. Eur J Clin Nutr 1995; 49(Suppl. 1): S13–18.

    PubMed  Google Scholar 

  156. von Mutius E. Progression of allergy and asthma through childhood to adolescence. Thorax 1996; 51(Suppl. 1): S3–6.

    Article  Google Scholar 

  157. Vasiliauskas EA. Monoclonal antibody therapy in inflammatory bowel disease. In: Bistrian BR, Walker-Smith JA, eds. Inflammatory Bowel Diseases: Nestlé Nutrition Workshop Series Clinical & Performance Programme. Basel: Nestec Ltd, Vevey/S. Karger AG, 1999: 237–55.

    Google Scholar 

  158. Targan SR, Hanauer SB, van Deventer SJH et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor a for Crohn’s disease. N Engl J Med 1997; 337: 1029–35.

    PubMed  CAS  Google Scholar 

  159. Sandborn WJ. Azathioprine: state of the art in inflammatory bowel disease. Scand J Gastroenterol 1998; 33(Suppl. 22): 92–9.

    CAS  Google Scholar 

  160. Dubinsky MC, Lamothe S, Yang HY et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000; 118: 705–13.

    PubMed  CAS  Google Scholar 

  161. Dubinsky M, Hassard PV, Yang H et al. 6-MP metabolite levels correlate with clinical response and drug toxicity in adult IBD. Am J Gastroenterol 1999; 94: 2641 (A258).

    Google Scholar 

  162. Dubinsky MC, Hassard PV, Kam L et al. Serial 6-mercaptopurine (6-MP) metabolite measurements in combination with dose escalation unmasks an important biochemical explanation for ‘6-MP resistance’. Gastroenterology 2000; 118:A890 (no. 4926).

    Google Scholar 

  163. Taylor KD, Vasiliauskas EA, Kam LY et al. Specific clinical and immunological features in Crohn’s disease pateints are associated with MHC Class III marker notch4. Gastroenterology 2000; 118: A869 (no. 4830).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. San Fernando Valley Gastroenterology Medical Group, Tarzana, CA, USA

    Lori Kam

  2. IBD Center Cedars-Sinai Medical Center, Los Angeles, CA, USA

    Eric A. Vasiliauskas (Associate Clinical Director and Assistant Professor)

  3. Medicine and Pediatrics UCLA School of Medicine, Los Angeles, CA, USA

    Eric A. Vasiliauskas (Associate Clinical Director and Assistant Professor)

Authors
  1. Lori Kam
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eric A. Vasiliauskas
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Cedars-Sinai IBD Center, Los Angeles, CA, USA

    Stephan R. Targan  & Loren C. Karp  & 

  2. Cork University Hospital, Cork, Ireland

    Fergus Shanahan

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Kluwer Academic Publishers

About this chapter

Cite this chapter

Kam, L., Vasiliauskas, E.A. (2003). New diagnostic approaches in inflammatory bowel disease. In: Targan, S.R., Shanahan, F., Karp, L.C. (eds) Inflammatory Bowel Disease: From Bench to Bedside. Springer, Boston, MA. https://doi.org/10.1007/0-387-25808-6_20

Download citation

  • DOI: https://doi.org/10.1007/0-387-25808-6_20

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-0-387-25807-2

  • Online ISBN: 978-0-387-25808-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation